OCUL

8.29

0.73% 0.06

Handel nachbörslich: 8.32 0.03 +0.36%

Ocular Therapeutix Inc (OCUL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt OCUL? Forum Prognose

Schlusskurs vom Vortag:

$8.23

Offen:

$8.21

24-Stunden-Volumen:

2.04M

Relative Volume:

0.49

Marktkapitalisierung:

$1.82B

Einnahmen:

$52.04M

Nettoeinkommen (Verlust:

$-290.50M

KGV:

-7.8185

EPS:

-1.0603

Netto-Cashflow:

$-216.89M

1W Leistung:

+3.75%

1M Leistung:

-12.64%

6M Leistung:

-31.71%

1J Leistung:

+13.56%

1-Tages-Spanne:

$8.14

$8.33

1-Wochen-Bereich:

$7.86

$8.36

52-Wochen-Spanne:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Firmenname

Ocular Therapeutix Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

781-357-4000

Adresse

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Mitarbeiter

325

Twitter

@OCUTX

Nächster Verdiensttermin

2026-05-05

Neueste SEC-Einreichungen

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCUL Ocular Therapeutix Inc	8.29	1.80B	52.04M	-290.50M	-216.89M	-1.0603
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-15	Eingeleitet	Chardan Capital Markets	Buy
2025-04-08	Eingeleitet	William Blair	Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-03-11	Eingeleitet	Needham	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-06-20	Hochstufung	TD Cowen	Hold → Buy
2024-05-31	Fortgesetzt	Piper Sandler	Overweight
2024-02-09	Eingeleitet	BofA Securities	Buy
2023-04-21	Eingeleitet	Robert W. Baird	Outperform
2022-08-10	Fortgesetzt	Berenberg	Buy
2021-08-10	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-17	Eingeleitet	Berenberg	Buy
2020-11-13	Bestätigt	Raymond James	Strong Buy
2020-08-10	Bestätigt	H.C. Wainwright	Buy
2020-03-03	Hochstufung	Raymond James	Outperform → Strong Buy
2019-05-21	Herabstufung	Cowen	Outperform → Market Perform
2019-05-21	Bestätigt	H.C. Wainwright	Buy
2019-05-21	Herabstufung	Raymond James	Strong Buy → Outperform
2018-12-03	Bestätigt	Cantor Fitzgerald	Overweight
2018-11-15	Eingeleitet	Raymond James	Strong Buy
2018-09-07	Eingeleitet	Piper Jaffray	Overweight
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-26	Eingeleitet	H.C. Wainwright	Buy
2017-07-12	Bestätigt	Cantor Fitzgerald	Overweight
2017-06-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Eingeleitet	Cantor Fitzgerald	Overweight
2016-11-15	Bestätigt	RBC Capital Mkts	Outperform
2016-08-11	Eingeleitet	JMP Securities	Mkt Outperform
2016-02-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

May 24, 2026

Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 24, 2026

May 22, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

May 22, 2026

May 20, 2026

Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Moomoo

May 20, 2026

May 19, 2026

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions? - simplywall.st

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Globe and Mail

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Motley Fool

May 19, 2026

May 17, 2026

Why (OCUL) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 17, 2026

May 15, 2026

[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 15, 2026

New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs - Stock Titan

May 15, 2026

May 13, 2026

Dole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market session - MSN

May 13, 2026

Neuropathic Ocular Pain Therapeutics Market Size (7MM) - openPR.com

May 13, 2026